Medicis Pharmaceutical Corporation

Medicis Pharmaceutical Coropration

R Todd Plott

Mitchell S Wortzman

Bhiku G Patel

Kuljit S Bhatia

Steven B Newhard

David Watt

An oral dosage form, including 65 mg of minocycline, an amount of lactose monohydrate, and an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is hydroxypropylmethylcellulose that is about 8.9+/&#x2212;0.2% hydroxypropoxylated. An oral dosage form, including 115 mg of minocycline, an amount of lactose monohydrate, and an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is hydroxypropylmethylcellulose that is about 8.9+/&#x2212;0.2% hydroxypropoxylated.

Method for the treatment of acne and certain dosage forms thereof

An oral dosage form has the following: an amount of minocycline selected from the group consisting of 55 mg, 80 mg, and 105 mg; an amount of lactose monohydrate; an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is at least 8.3 to about 9.8% hydroxypropoxylated. The minocycline in the oral dosage form has a dissolution profile or release rates about 35% to about 50% in 1 hour, about 60% to about 75% in 2 hours, and at least about 90% in 4 hours. There is also provided a method of treating acne in a human and a method of assisting a physician in prescribing a dose of minocycline for the treatment of acne.

Extended-release minocycline dosage forms

Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.

Minocycline oral dosage forms for the treatment of acne

A method for treatment of acne with tetracyclines is provided. A lower sustained dose and no loading dose is employed, with an optional once-a-day dosing regimen.

Growing community of inventors

Briscoe, TX, United States of America

R Todd Plott